Definition, deliverables, and the operations boundary
Clinical trial protocol design converts a valuable and answerable sleep health question into a prespecified, ethical, statistically identifiable, and operationally feasible research blueprint. It belongs to WSIC 6.5.1, Clinical Trial Services. Deliverables commonly include the protocol and synopsis, schedule of visits and assessments, intervention and comparator descriptions, endpoint definitions, statistical principles, safety monitoring, data and quality frameworks, information needed for consent, and references to manuals and supporting plans. The protocol must let investigators implement a consistent method and let participants, ethics committees, statisticians, regulators, and later readers understand why the trial is needed, what will be measured, how comparisons will be made, and when the trial may stop.
This service is distinct from the preceding multi-center operations entry, document formatting, outsourced statistical calculation, ethics or regulatory approval, data management, and publication. Design work can use simulation, interviews, and feasibility exercises to discover implementation barriers, but operational convenience is not a scientific or ethical justification, and operations teams cannot silently alter the design during conduct. Templates, checklists, and structured electronic formats improve completeness and reuse but cannot repair a wrong question, invalid endpoint, biased comparison, or inadequate sample size. The final protocol needs review and approval by accountable people with suitable medical, statistical, methodological, patient-engagement, and implementation expertise.
Research question, evidence foundation, and estimands
Design begins with existing evidence, unresolved uncertainty, the intended decision, and issues important to patients. It should state whether the study is exploratory, dose finding, mechanistic, or a feasibility trial, or intended to confirm efficacy, safety, or comparative effects. The question identifies the target population, intervention, comparator, outcome, observation period, and setting and explains why a trial is needed and why the chosen design adds knowledge. Early input from patients, caregivers, sleep technologists, and clinicians can expose overnight-test burden, withdrawal of existing therapy, next-day driving, caregiver impact, digital exclusion, and outcomes that matter. That input should be documented transparently; a small convenience group cannot represent every patient.
The primary objective should map to an explicit estimand: the population, treatment conditions to compare, outcome variable, strategy for intercurrent events such as discontinuation, rescue, switching, nonadherence, device failure, loss to follow-up, or death, and the population-level summary. A superiority, noninferiority, equivalence, or descriptive purpose needs a compatible comparator, margin, hypothesis, and interpretation; a noninferiority margin must not be selected merely to reduce sample size. A protocol may address several questions, but it should distinguish primary, key secondary, other secondary, and exploratory objectives so that a favorable result is not selected after the fact from a large set of analyses.
Population, sites, interventions, randomization, and blinding
Eligibility criteria should directly serve the research question, participant safety, and applicability and justify restrictions based on diagnosis, stage, comorbidities, existing treatment, age, language, or technical ability. Excessive exclusion of older adults, people with comorbidity, shift workers, different regions, or limited digital access creates a sample unlike the intended-use population. People needing added protections should not be excluded without reason, nor should protection be lowered because recruitment is difficult. The protocol also defines site, investigator, and equipment qualifications and estimates screening sources, competing studies, attrition, and center variation, so that sample size is not detached from recruitment and resource reality.
Intervention and comparator descriptions should permit replication, covering composition, dose or intensity, timing, duration, escalation, allowed concomitant care, rescue, interruption, adherence, delivery personnel, and training. The randomization unit, sequence generation, stratification or blocking, allocation concealment, and implementation roles should be specified to prevent prediction of assignment. Blinding should state who is blinded, how it is maintained, whether interventions appear similar, how emergency unblinding works, and how blind compromise is assessed. With devices, PAP, oral appliances, light or sound environments, digital therapeutics, or behavioral interventions, a sham may not fully mask assignment. The design should address expectations, contact time, and co-intervention differences instead of merely applying a double-blind label.
Sleep endpoints, measurement windows, and technology fitness
Endpoints should represent how participants feel, function, or survive or biological and behavioral changes that legitimately support the intended decision. Clinical outcomes, surrogates, performance measures, and exploratory digital features should remain distinct. A primary endpoint defines the variable, scale or event, calculation, baseline, time window, repeated-measure summary, direction, and clinical interpretation. AHI, REI, RDI, sleep efficiency, total sleep time, sleep latency, arousal, hypoxic burden, and patient-reported outcomes cannot be specified by acronym alone because their numerators, denominators, scoring rules, and settings may differ. Multiple endpoints, times, doses, subgroups, or analyses raise the risk of false conclusions and call for a prespecified hierarchy, composite rule, or multiplicity strategy rather than treating every positive result as confirmatory.
PSG, HSAT, actigraphy, questionnaires, diaries, wearables, and contactless sensing require controlled device and firmware, channels or sensors, sampling, filters, units, clocks, calibration, laboratory or home setting, number of nights, valid-record criteria, repeats, wear and non-wear handling, algorithm and scoring-rule versions, central reading, and quality review. A digital technology needs sufficient analytical and clinical validation for the specific population, setting, and purpose. A consumer sleep score or automated staging output does not become a valid endpoint merely because it is easy to collect. The design should anticipate first-night effects, night-to-night variability, time zones, shift work, device replacement, software updates, and home connectivity loss and state how these conditions enter estimation and missing-data handling.
Sample size, analysis, and missing data
Sample-size justification should state the primary estimand, comparison, expected effect or precision, variability, event rate, significance level, power, allocation ratio, attrition, adherence, clustering or repeated measurement, and multiplicity assumptions, with the source and uncertainty of each input. A small pilot or feasibility study can estimate recruitment, processes, and measurement parameters but should not present an imprecise efficacy signal as confirmation. The number of centers, participants per center, extreme imbalance, center effects, and device batches can all change information. If an adaptive design, sample-size re-estimation, or interim analysis is used, decision rules, information barriers, error control, and operational feasibility need prespecification.
The statistical section aligns analysis population, model, covariates, baseline, center, repeated measures, effect measure, interval estimation, and hypothesis tests with the estimand. Intercurrent events such as discontinuation, crossover, rescue, intervention change, and death are not the same as missing data caused by non-wear, corrupted signals, or loss to follow-up, and each needs separate strategies and assumptions. Primary, sensitivity, and supplementary analyses need distinct roles, with sensitivity analyses testing robustness to unverifiable assumptions. Complete-case or adherent-only analysis is not a default remedy. Subgroup and exploratory analyses should specify interaction methods, prior rationale, and restrained interpretation and must not mistake significance within one subgroup and non-significance in another for evidence of a subgroup difference.
Safety, ethics, data quality, and feasibility
The protocol should describe risk and benefit, known and foreseeable harms, adverse-event definitions and collection, safety assessments, emergencies, medical monitoring, pause or stop rules, need for independent monitoring, pregnancy or device-deficiency handling, and post-trial arrangements. Sleep studies may also encounter material hypoxemia or cardiac findings, daytime sleepiness and driving risk, falls, skin injury, home electrical hazards, withdrawal of therapy, and incidental findings. Response paths should be proportionate to the research purpose and local care capacity. Consent, privacy, compensation, injury, vulnerability, equitable recruitment, conflicts, and results disclosure belong in design and should not be left for sites to improvise.
Quality comes from feasible design. Critical-to-quality factors such as consent, eligibility, randomization, intervention, primary outcomes, safety, and blinding should be identified, while unrelated data and burdensome procedures are removed. The schedule, case-report forms, laboratory and scoring manuals, data flows, monitoring plan, and statistical plan must agree. Remote visits, electronic consent, direct-to-participant delivery, and digital capture need identity, location, support, abnormal-result escalation, downtime, and fallback provisions. Pilots, tabletop exercises, and cross-disciplinary review should test windows, fields, logic, devices, site resources, and participant burden. Infeasibility discovered before approval should change the design rather than be managed later through repeated deviations.
Version governance, transparency, and claim boundaries
A protocol needs a unique identifier, title, date, version, accountable authors, and approvals, with controlled dependencies among the main text, synopsis, statistical plan, consent, registry record, manuals, and system configuration. An amendment should explain its reason, exact changes, risk, effect on enrolled participants, need for re-consent, approvals, and effective date while preserving prior versions and change history. Trials should be prospectively registered when required; protocols and statistical plans should be accessible where appropriate; and dissemination, participant communication, authorship, data and code sharing, confidentiality, and retention should be planned. Negative, null, or early-terminated results should not disappear because they are inconvenient.
Design acceptance can trace each question through objective, estimand, endpoint, and analysis and check operational feasibility, safety routes, minimization, multiplicity, missing-data assumptions, version consistency, and conflicts. SPIRIT or a structured template can check content; neither is a quality score nor regulatory approval. Protocol design cannot guarantee recruitment, adherence, freedom from bias, statistical significance, clinical benefit, product authorization, or global compliance, and exploratory endpoints must not be marketed as confirmatory evidence. A mature service discloses evidence gaps, assumptions, tradeoffs, residual bias, and issues requiring ethics or regulatory discussion so the protocol can be challenged, implemented, analyzed, and reported faithfully.